Anatara Lifesciences (ASX:ANR) said it is unlikely to achieve a statistically significant improvement in irritable bowel syndrome severity scoring system when compared to placebo in the second stage of the phase two Gastrointestinal ReProgramming-IBS trial based on preliminary analysis, according to a Monday Australian bourse filing.
It said the second stage of the trial moved into the database lock process after all participants completed the mandatory two-week follow-up period.
The final fully assessable number of participants has been reduced to 62 from 71 after the assessment of participant numbers for both compliance and entry criteria.
The second stage included a planned extension of the phase two trial, following the successful completion of stage 1 which reported on 20 patients with a greater than 50% reduction in IBS symptoms and with a safety profile confirmed.
It added that its planned anti-obesity in-vivo pre-clinical experiments are now underway following agreements with the University of Newcastle.
Its shares fell 74% in recent trading on Monday, reaching an all-time low.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.